Note: This document is a translation of the original Japanese version and provided for reference purposes only. In the event of any discrepancy between the Japanese original and this English translation, the Japanese original shall prevail.

Press Release

ASKA Pharmaceutical Holdings Co., Ltd.

Personnel Changes in Board Members and Corporate Officers

TOKYO, May 11, 2026 - ASKA Pharmaceutical Holdings Co., Ltd. (Head Office: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi) announced the following personnel changes of the board members and the corporate officers. The nominations are supposed to be effective on June 24, 2026.

The Company plans to propose changes to the members of the board of directors, including audit & supervisory committee members, at the 5th Ordinary General Meeting of Shareholders scheduled to be held on June 24, 2026. Changes in corporate officers are scheduled to be resolved at a meeting of the Board of Directors to be held after the General Meeting of Shareholders.

1. Personnel Changes to the Board Members

(1) Members of the Board of Directors (excluding Board Members who are Audit & Supervisory Committee Members)

James C. Feliciano	[New Responsibilities] Member of the Board of Directors *Newly appointed [Current Responsibilities] -

(2) Board Members who are Audit & Supervisory Committee Members

Kunihiro Gunji	[New Responsibilities] Member of the Board of Directors, Audit & Supervisory Committee Member * Newly appointed [Current Responsibilities] Audit & Supervisory Board Member
Takao Kimura	[New Responsibilities] Member of the Board of Directors, Audit & Supervisory Committee Member * Newly appointed [Current Responsibilities] Audit & Supervisory Board Member
Koki Yamashita	[New Responsibilities] Member of the Board of Directors, Audit & Supervisory Committee Member * Newly appointed [Current Responsibilities] Audit & Supervisory Board Member

Mr. Kazuhiro Chiku, current Audit & Supervisory Board Member, is scheduled to retire at the conclusion of the 5th Ordinary General Meeting of Shareholders scheduled to be held on June 24, 2026.

(3) Candidate for Alternate Board Member who is Audit & Supervisory Committee Member

Takeru Nishino	[New Responsibilities] Member of the Board of Directors, Audit & Supervisory Committee Member * Newly appointed [Current Responsibilities] -

2. Personnel Change to the Corporate Officers
   Mr. Junichi Saito, current Corporate Officer (Members of the Board of Directors of ASKA Pharma Medical Co., Ltd.), is scheduled to retire at the meeting of the Board of Directors to be held after the conclusion of the 5th Annual General Meeting of Shareholders scheduled for June 24, 2026.

3. Biographical Summary of the Newly Appointed Board Member
   Name: James C. Feliciano
   Date of Birth: September 22, 1969
   Career Summary:

October 2009:	General Manager, Vaccine Business Unit, Pfizer Japan Inc.
November 2013:	President and Representative Director, Merck Serono K.K. (currently Merck Biopharma Co., Ltd.)
June 2015:	President, AbbVie G.K.
End of October 2024:	Retired as President, AbbVie G.K.
March 2025:	President, 3C Advisors G.K.(current position)
December 2025:	Surzen Biotherapeutics K.K., Chief Executive Officer (current position)

Reference (As of June 24, 2026)

1. Board Members (excluding Board Members who are Audit & Supervisory Committee Members)

Takashi Yamaguchi	Member of the Board of Directors, Representative Director, Chairman of the Board (Member of the Board of Directors, Representative Director, Chairman of the Board of ASKA Pharmaceutical Co., Ltd.)
Sohta Yamaguchi	President, Member of the Board of Directors, Representative Director (President, Member of the Board of Directors, Representative Director of ASKA Pharmaceutical Co., Ltd.)
Atsushi Maruo	Senior Managing Member of the Board of Directors, Representative Director, In Charge of Sustainability (Member of the Board of Directors, Vice Chairman of the Board of ASKA Pharmaceutical Co., Ltd.)
Maiko Mori	Member of the Board of Directors, Executive Corporate Officer (Member of the Board of Directors, Executive Corporate Officer, Quality & Safety Assurance Division Director of ASKA Pharmaceutical Co., Ltd.)
Fumiyoshi Yamaguchi	Member of the Board of Directors, Executive Corporate Officer (President, Member of the Board of Directors, Representative Director of ASKA Animal Health Co., Ltd.)
Minoru Awabayashi	Member of the Board of Directors, Outside Director
Yasuji Enokido	Member of the Board of Directors, Outside Director
Kanae Karita	Member of the Board of Directors, Outside Director
Kiyoko Kato	Member of the Board of Directors, Outside Director
James C. Feliciano	Member of the Board of Directors, Outside Director

2. Board Members who are Audit & Supervisory Committee Members

Kunihiro Gunji	Member of the Board of Directors, Audit and Supervisory Committee Member (Audit & Supervisory Board Member of ASKA Pharmaceutical Co., Ltd., Audit & Supervisory Board Member of ASKA Pharma Medical Co., Ltd.)
Takao Kimura	Member of the Board of Directors, Outside Director, Audit and Supervisory Committee Member
Koki Yamashita	Member of the Board of Directors, Outside Director, Audit and Supervisory Committee Member

3. Corporate Officers

Kiyohiko Tamura	Executive Corporate Officer Group Business Management Division Director In Charge of DX Promotion (Executive Corporate Officer, Administrative Division Director of ASKA Pharmaceutical Co., Ltd.)
Tomohito Nagao	Corporate Officer In Charge of Audit and Legal Affairs & Regulatory Compliance (Corporate Officer, Director, Information service Supervisory Unit of ASKA Pharmaceutical Co., Ltd.)
Hidenori Hori	Corporate Officer (President, Member of the Board of Directors, Representative Director of ASKA Pharma Medical Co., Ltd.)

Media Contacts
ASKA Pharmaceutical Holdings Co., Ltd.
Corporate Planning Department
Tel: +81-3-5484-8366
Email: kouhou@aska-pharma.co.jp